Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety
Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.
You may also be interested in...
Cybin CEO: Big Pharma Can No Longer Sit On The Sidelines In Psychedelics
Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.
Cryptic Terran Licences Advanced CNS Assets From Sanofi
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
IQVIA COVID-19 Vaccine Revenues To Soar But Pandemic Will Impact Overall Global Medicine Spending
While more money will be poured into COVID-19 vaccines, the pandemic's effects will be felt on overall growth of global medicine use following disruptions to patient engagement with healthcare, a new report from the IQVIA Institute for Human Data Science predicts.